Haist, M.; Stege, H.; Ebner, R.; Fleischer, M.I.; Loquai, C.; Grabbe, S.
The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study. Cancers 2022, 14, 2082.
https://doi.org/10.3390/cancers14092082
AMA Style
Haist M, Stege H, Ebner R, Fleischer MI, Loquai C, Grabbe S.
The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study. Cancers. 2022; 14(9):2082.
https://doi.org/10.3390/cancers14092082
Chicago/Turabian Style
Haist, Maximilian, Henner Stege, Ronja Ebner, Maria Isabel Fleischer, Carmen Loquai, and Stephan Grabbe.
2022. "The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study" Cancers 14, no. 9: 2082.
https://doi.org/10.3390/cancers14092082
APA Style
Haist, M., Stege, H., Ebner, R., Fleischer, M. I., Loquai, C., & Grabbe, S.
(2022). The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study. Cancers, 14(9), 2082.
https://doi.org/10.3390/cancers14092082
